<DOC>
	<DOCNO>NCT00985192</DOCNO>
	<brief_summary>RATIONALE : Everolimus may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study well everolimus work treat patient previously treat unresectable metastatic esophageal cancer stomach cancer .</brief_summary>
	<brief_title>Everolimus Treating Patients With Previously Treated Unresectable Metastatic Esophageal Cancer Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine overall disease-control rate ( complete response , partial response , stable disease ) patient previously treat unresectable metastatic adenocarcinoma upper gastrointestinal tract treat everolimus . Secondary - To determine safety toxicity everolimus patient . - To determine efficacy everolimus , term time response , duration response , time tumor progression , progression-free survival , overall survival , patient . - To explore potential correlation clinical outcome biomarkers interest , include S6 protein overexpression and/or mTOR-related protein blood tumor biopsy sample patient . OUTLINE : This multicenter study . Patients receive oral everolimus daily day 1-14 . Courses repeat every 14 day absence disease progression unacceptable toxicity . Blood , serum , tumor tissue sample collect biomarker analysis . After completion study treatment , patient follow every 3 month 1 year every 6 month thereafter .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : Diagnosis adenocarcinoma upper gastrointestinal tract Metastatic unresectable disease Received 12 prior chemotherapy biological therapy regimens unresectable metastatic disease Measurable disease ≥ 1 dimension CT scan MRI Patients whose measurable lesion metastatic lymph node eligible provide permission principal investigator ECOG performance status 01 Life expectancy &gt; 3 month ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN ( ≤ 5.0 time ULN liver metastasis ) Creatinine clearance &gt; 60 mL/min Fasting serum cholesterol &lt; 300 mg/dL &lt; 7.75 mmol/L* Fasting triglycerides &lt; 2.5 time ULN* INR ≤ 3.5 ( patient warfarin ) Negative pregnancy test Fertile patient must use effective contraception ≥ 4 month completion study treatment ( oral , implantable , injectable contraceptive consider effective contraception study ) More 30 day since prior chemotherapy , surgery , radiotherapy , investigational agent uncontrolled diabetes mellitus , define fast serum glucose &gt; 1.5 time ULN severely impair lung function know HV infection active , bleed diathesis unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction within past 6 month serious uncontrolled cardiac arrhythmia active uncontrolled infection require parenteral antimicrobial know liver disease ( e.g. , cirrhosis , chronic active hepatitis , chronic persistent hepatitis ) inability swallow , impaired gastrointestinal ( GI ) function , GI disease ( e.g. , ulcerative colitis , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) would significantly alter absorption study drug preclude use oral medication malignancy within past 5 year except nonmelanoma skin cancer cervical carcinoma situ know hypersensitivity everolimus , sirolimus , temsirolimus excipients medical condition , opinion investigator , would preclude study participation prior mTOR inhibitor ( e.g. , rapamycin , CCI779 ) concurrent chronic treatment steroid another immunosuppressive agent concurrent prophylactic use hematopoietic growth factor concurrent anticancer agent therapy ( include radiotherapy ) concurrent experimental agent concurrent strong inhibitor inducer isoenzyme CYP3A4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
</DOC>